1. Mesenchymal stromal cell-derived extracellular vesicles as nanotherapeutics for concanavalin a-induced hepatitis: modulating the gut‒liver axis.
- Author
-
Yang F, Ni B, Liang X, He Y, Yuan C, Chu J, Huang Y, Zhong H, Yang L, Lu J, Xu Y, Zhang Q, and Chen W
- Subjects
- Animals, Mice, Male, Gastrointestinal Microbiome drug effects, Disease Models, Animal, Concanavalin A, Extracellular Vesicles metabolism, Mesenchymal Stem Cells metabolism, Mice, Inbred C57BL, Hepatitis, Autoimmune therapy, Hepatitis, Autoimmune metabolism, Hepatitis, Autoimmune pathology, Hepatitis, Autoimmune drug therapy, Liver metabolism, Liver pathology, Liver drug effects
- Abstract
Background: As cell-free nanotherapeutics, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have shown potential therapeutic action against liver diseases. However, their effects on autoimmune hepatitis (AIH) are not yet well understood., Methods and Results: In this study, we utilized a well-established concanavalin A (Con A)-induced fulminant hepatitis mouse model to investigate the effects of MSC-EVs on AIH. We found that MSC-EVs provide significant protection against Con A-induced hepatitis in C57BL/6 male mice, with their effectiveness being critically dependent on the gut microbiota. MSC-EVs modulate the composition of the gut microbiota, particularly by increasing the abundance of norank_f__Muribaculaceae, and impact liver metabolic profiles, leading to significant amelioration of liver injury. The identification of Acetyl-DL-Valine as a protective metabolite underscores the therapeutic potential of targeting gut‒liver axis interactions in liver diseases., Conclusion: Overall, our data demonstrate that MSC-EVs exhibit nanotherapeutic potential in Con A-induced hepatitis and provide new insights into the treatment of autoimmune hepatitis., Competing Interests: Declarations. Ethics approval and consent to participate: All experiments were performed in accordance with the institutional guidelines of the Third Affiliated Hospital of Sun Yat-sen University. The use of animals in this study was approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University and was conducted in accordance with the ARRIVE guidelines 2.0. The approved study is titled “Mechanism of mesenchymal stem cells in relieving ConA-induced liver failure”, with approval granted on December 25, 2023 (Approval number: IACUC-F3-24-0102). The umbilical cords were obtained from healthy mothers at the Third Affiliated Hospital of Sun Yat-sen University with parental consent. The procedure for isolating UC-MSCs was approved by the Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. The approved study is titled “A Multicenter Randomized Controlled Clinical Study on the Treatment of Hepatitis B-Related Acute-on-Chronic Liver Failure with Allogeneic Human Umbilical Cord Mesenchymal Stem Cells”, with approval granted on December 30, 2020 (Approval number: 2020-14). Informed consent was obtained from all the subjects and/or their legal guardian(s) under the ethical committee of the Third Affiliated Hospital of Sun Yat-sen University. Consent for publication: All the authors confirm their consent for publication. Competing interests: The authors declare that they have no competing financial interests or personal relationships that could have influenced the work reported in this paper., (© 2024. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF